PORTFOLIO

Aclaris Therapeutics (NASDAQ: ACRS) is a specialty pharmaceutical company focused on the development of novel dermatological therapies.
Advanced Accelerator Applications (NASDAQ: AAAP) is pioneering the field of Molecular Nuclear Medicine and aims to provide predictive, preventive and personalized tools and procedures that will radically transform healthcare management both for healthcare professionals and patients.
Agile Therapeutics (NASDAQ: AGRX) is a specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products.
AirXpanders (ASX: AXP) is a medical device company that has developed the AeroForm tissue expander. AeroForm is a patient controlled breast tissue expander for reconstructive surgeries such as breast reconstruction after mastectomy.
Akari Therapeutics (NASDAQ: AKTX) is developing anti-complement and anti-inflammatory molecules as life-transforming treatments for a wide range of severe and orphan autoimmune and inflammatory diseases.
Ascendis Pharma (NASDAQ: ASND) develops differentiated prodrug versions of high-value drugs. The company’s proprietary TransCon technology is used to generate product candidates that are improved versions of existing drugs, yielding more effective, lower-risk therapeutics with new patent lives.
Biohaven Pharma is a privately-held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting orphan neurologic indications and other neurological pathways.
BioPharmX (NYSE: BPMX) provides innovative healthcare products through its unique, patented platform technologies for pharmaceutical, over-the-counter (OTC), and supplement applications.
Capnia (NASDAQ: CAPN) is developing novel medical diagnostics and therapeutics based on their proprietary technology for precision metering of gas flow.
Carbylan Therapeutics (NASDAQ: CBYL) is developing a next generation product combining hyaluronic acid and steroid for the treatment of osteoarthritis.
Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of Hepatitis. Our pipeline includes preclinical NCEs from discovery as well as repurposed clinical agents to treat Hepatitis C and Hepatitis D.
Essentialis is developing a novel therapy for the treatment of dyslipidemia.
Foamix (NASDAQ: FOMX) is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.
Impel NeuroPharma is using its Precision Olfactory Delivery (POD) nasal devices to develop therapies for diseases of the brain such as migraine and Alzheimer’s.
MacroGenics (NASDAQ: MGNX) is developing antibodies and vaccines in the areas of oncology, inflammation, allergy, and infectious diseases.
MEI Pharma (NASDAQ: MEIP) is focused on the clinical development of novel therapies for cancer. MEI’s programs include a potential best-in-class HDAC inhibitor, Pracinostat, and isoflavone-based compounds ME-143 and ME-344.
Minerva Surgical is developing next-generation technology for treating excessive menstrual bleeding.
Nabriva (NASDAQ: NBRV) is an anti-infective company developing a novel therapy for Community Acquired Pneumonia.
Nora Therapeutics is developing novel treatments in reproductive medicine.
Ocera Therapeutics (NASDAQ: OCRX) is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet clinical need.
OncoGenex Pharmaceuticals (NASDAQ: OGXI) is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients.
Outpost Medicine is developing novel therapy for stress urinary incontinence.
ProNAi Therapeutics (NASDAQ: DNAI) is developing a new class of therapies that target genomic DNA to treat patients with cancer and other diseases.
REGENXBIO (NASDAQ: RGNX) is a gene therapy platform company that is leveraging its proprietary NAV® Technology to advance the development of life-changing adeno-associated viral (AAV) treatments for lysosomal storage disorders, ocular diseases, and other unmet clinical needs.
Revance Therapeutics (NASDAQ: RVNC) is a specialty pharmaceutical company focused on discovering and developing therapeutic products in the areas of aesthetic medicine and therapeutic dermatology.
Semnur Pharmaceuticals is a pharmaceutical company developing an injectable product for the treatment of lower back pain.
SentreHEART is a commercial stage medical device company with a novel suture delivery and tissue closure device for multiple clinical applications.
Synapse BioMedical is a medical device company developing neurostimulation products. The company’s products have been approved by the FDA for patients with spinal cord injury and amyotrophic lateral sclerosis.
Trevena, Inc. (NASDAQ: TRVN) is a clinical stage biopharmaceutical company focused on discovering and developing biased ligands to deliver the next generation of GPCR targeted medicines.
TRIA Beauty is a leader in light-based therapeutic beauty systems that incorporate clinically-proven aesthetic technologies for at-home personal care regimens.
Verona Pharma (LSE AIM:VRP.L) is focused on developing new drugs for a range of respiratory diseases.